Swiss mortality shifts: Cancer overtakes heart disease as top killer in 2024
Swiss mortality shifts: Cancer overtakes heart disease as top killer in 2024
Swiss mortality shifts: Cancer overtakes heart disease as top killer in 2024
Switzerland recorded nearly 72,000 deaths among its permanent residents in 2024. Official figures show a slight drop in fatalities linked to cardiovascular diseases, though they remained a leading cause of death. Meanwhile, cancer-related deaths rose for both men and women during the same period.
In 2024, around 35,000 men and 37,000 women in Switzerland's permanent resident population died. Cardiovascular diseases accounted for over a quarter of all deaths, though their overall rate fell compared to 2023.
Cancer became the most common cause of death for men, responsible for 28% of cases, while cardiovascular diseases followed closely at 27%. For women, cardiovascular diseases remained the leading cause at 29%, with cancer second at 22%.
The data also revealed a rise in deaths from dementia among men. Conversely, fatalities from external causes—such as accidents, violence, and suicides—declined for both genders.
The 2024 figures highlight shifting trends in Switzerland's mortality rates. While fewer people died from cardiovascular diseases and external causes, cancer and dementia-related deaths increased. These changes reflect evolving health challenges in the country.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?